NOS3 Knockout A-549 Cell Line
Cat.No.:
EDC08396
Species:
Human
Cell Name:
A-549
Gene:
NOS3
Gene ID:
4846
Size:
1×10⁶ cells
NOS3 Knockout Cell Line (A549) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC08396 |
|---|---|
| Product Name | NOS3 Knockout A549 Cell Line |
| Cell Line | A-549 |
| Cellosaurus ID | CVCL_0023 |
| Cell Line Synonyms | A 549, A549, NCI-A549, A549/ATCC, A549 ATCC, A549ATCC, hA549 |
| Gene | NOS3 |
| NCBI Gene ID | |
| Gene Synonyms | ECNOS|eNOS |
| Summary |
Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. Nitric oxide is synthesized from L-arginine by nitric oxide synthases. Variations in this gene are associated with susceptibility to coronary spasm. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, Oct 2016]
|
| Associated Diseases | Non-Small Cell Lung Carcinoma |
| Morphology | Adherent |
| Passage Ratio | 1/5-1/4, 2days |
| Complete Culture Medium | F-12K + 10% FBS |
| Freezing Medium | 95% Complete culture medium + 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: A-549 | STR Info (Cell bank) Cell Line: A-549 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | Y | X | Y |
| CSF1PO | 10 | 12 | 10 | 12 |
| D2S1338 | 24 | 24 | ||
| D3S1358 | 16 | 16 | ||
| D5S818 | 11 | 11 | ||
| D7S820 | 8 | 11 | 8 | 11 |
| D8S1179 | 13 | 14 | 13 | 14 |
| D13S317 | 11 | 11 | ||
| D16S539 | 11 | 12 | 11 | 12 |
| D18S51 | 14 | 17 | 14 | 17 |
| D19S433 | 13 | 13 | ||
| D21S11 | 29 | 29 | ||
| FGA | 23 | 23 | ||
| Penta D | 9 | 9 | ||
| Penta E | 7 | 11 | 7 | 11 |
| TH01 | 8 | 9.3 | 8 | 9.3 |
| TPOX | 8 | 11 | 8 | 11 |
| vWA | 14 | 14 | ||
| D6S1043 | 11 | 13 | ||
| D12S391 | 18 | 18 | ||
| D2S441 | 10 | 13 | 10 | 13 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying NOS3 function, NOS3 Knockout A-549 Cell Line or NOS3 overexpression A-549 Cell Line?
The choice depends on whether you are studying NOS3 (endothelial nitric oxide synthase, eNOS)'s role as the principal calcium/calmodulin-regulated nitric oxide synthase or its emerging functions in pulmonary epithelial biology. The Knockout line is the standard tool for asking whether eNOS is required for nitric oxide generation — eNOS is constitutively expressed in endothelial cells and is a key regulator of vascular tone through NO-mediated cGMP signaling in smooth muscle. Overexpression is useful for studying eNOS in non-endothelial contexts.
Important consideration: eNOS is principally expressed in endothelial cells — A-549 (lung adenocarcinoma) is not the physiological context for canonical eNOS endothelial function. The EDITGENE NOS3 Knockout in A-549 is most useful for in vitro biochemistry, eNOS inhibitor specificity testing, and studies of eNOS contribution to lung cancer biology where it has been characterized. Rescue with wild-type, oxygenase-dead (heme-binding mutations), or reductase-dead eNOS enables structure-function studies. The knockout is a critical specificity control for NOS inhibitors (L-NAME, L-NIO, and isoform-selective compounds).
What are the application scenarios for this model?
Primary applications:
• NO generation: cellular NO measurement following calcium stimulation or shear stress in eNOS-null versus rescued context.
• cGMP signaling: cGMP measurement and downstream PKG substrate analysis given NO-soluble guanylyl cyclase-cGMP signaling axis.
• Lung cancer biology: studies of eNOS contributions to lung cancer phenotypes given its emerging roles.
• NOS inhibitor specificity: critical genetic control for L-NAME (pan-NOS), L-NIO, and isoform-selective inhibitors.
EDITGENE recommends this model for in vitro eNOS biochemistry and NOS pharmacology research; physiological endothelial eNOS research requires endothelial cell models.
Is this NOS3 Knockout A-549 Cell Line compatible with overexpression rescue experiments?
Yes. eNOS rescue experiments require attention to multi-domain architecture:
• Construct design: use a codon-modified NOS3 sequence with a small C-terminal tag (FLAG, HA). eNOS has N-terminal oxygenase domain (heme, BH4 binding), CaM-binding region, and C-terminal reductase domain (FMN, FAD, NADPH) — preserve all elements.
• Oxygenase-dead rescue: heme-binding residue mutations abolish NO synthesis from L-arginine and serve as the standard specificity control.
• Reductase-dead rescue: NADPH-binding region mutations abolish electron transfer.
• Functional readout: rescue should restore NO generation measured by DAF-FM imaging or nitrite/nitrate quantification.
A-549 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.